Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Last updated on April 2022Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 300
Inclusion Criteria
- Breast cancer patients with any receptor type
- Women, 18 years of age and older.
- English speaking
- ...
- Breast cancer patients with any receptor type
- Women, 18 years of age and older.
- English speaking
- Able to participate in the informed consent process
- Postmenopausal women at time of diagnosis who have been without period for ≥ 2 years.
- Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
Exclusion Criteria
- Prior systemic treatment for a malignancy
- Active secondary cancer requiring cytotoxic chemotherapy
- Prior systemic treatment for a malignancy
- Active secondary cancer requiring cytotoxic chemotherapy
Summary
- Conditions
- Breast Cancer
- Hodgkin's Lymphoma
- Lymphoma
- Type
- Observational
- Design
- Observational Model: Cohort
- Time Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only females
Inclusion Criteria
- Breast cancer patients with any receptor type
- Women, 18 years of age and older.
- English speaking
- ...
- Breast cancer patients with any receptor type
- Women, 18 years of age and older.
- English speaking
- Able to participate in the informed consent process
- Postmenopausal women at time of diagnosis who have been without period for ≥ 2 years.
- Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
Exclusion Criteria
- Prior systemic treatment for a malignancy
- Active secondary cancer requiring cytotoxic chemotherapy
- Prior systemic treatment for a malignancy
- Active secondary cancer requiring cytotoxic chemotherapy
Tracking Information
- NCT #
- NCT01788839
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Shari Goldfarb, MD Memorial Sloan Kettering Cancer Center
- Shari Goldfarb, MD Memorial Sloan Kettering Cancer Center
Get Well Soon